SUZUKI Hiroyuki

写真a

Title

Professor

Date of Birth

1966

Research Fields, Keywords

Surgical Treatment for lung cancer, Chemotherapy for lung cancer, Multimodality therapy for thoracic malignancy, Cancer immunotherapy, Molecular biology for lung cancer, Tumor immunology, Adenocarcinoma lung, Glycoproteins,

Mail Address

E-mail address

Homepage URL

http://www.fmu.ac.jp/cms/surg1/index/

Current Affiliation Organization 【 display / non-display

  • Duty ,  School of Medicine (Clinical Medicin) ,  Department of Chest Surgery ,  Professor

Field of expertise (Grants-in-aid for Scientific Research classification) 【 display / non-display

  • Other

  • Respiratory surgery

  • Thoracic Surgery

 

Research Career 【 display / non-display

  • Oncological

  • Cancer Immunity

  • Molecular Biology of Lung Cancer

Papers 【 display / non-display

  • Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab.

    Hiroyuki Minemura, Hiroshi Moriya, Hisao Imai, Tomohide Sugiyama, Yutaka Yamada, Mitsunori Higuchi, Kyoichi Kaira, Yuki Ozaki, Kenya Kanazawa, Hiroshi Yokouchi, Takashi Kasai, Takayuki Kaburagi, Hiroyuki Suzuki, Koichi Minato, Yoko Shibata.

    Thoracic Cancer ,  11 (12) 3521 - 3527 ,  2020.12

    Multiple Authorship ,  ISBN: 17597706

    DOI PubMed

  • Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with EGFR-TKIs plus Bevacizumab: A Case Report.

    Satoshi Muto, Yuki Ozaki, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Yutaka Shio, Yuko Hashimoto, Hiroyuki Suzuki.

    Case Reports in Oncology ,  13 (3) 1387 - 1392 ,  2020.11

    Multiple Authorship ,  ISBN: 16626575

    DOI PubMed

  • Current status and prospect of medical and surgical management for thoracic empyema.

    Mitsunori Higuchi, Hiroyuki Suzuki.

    Current Challenges in Thoracic Surgery ,  2   39 ,  2020.11

    Multiple Authorship ,  ISBN: 26643278

    DOI

  • Significant discrepancies in serum SCC antigen levels by different immunoassays in a resected thymoma.

    Mitsunori Higuchi, Kazuya Watanabe, Takuro Saito, Masayuki Watanabe, Hiroyuki Suzuki.

    The Journal of the Japanese Association for Chest Surgery ,  34 (7) 740 - 745 ,  2020.11

    Multiple Authorship ,  ISBN: 09190945

    DOI CiNii

  • Monitoring Tumor Infiltrating Lymphocytes by Peripheral Blood in Lung Cancer Patients.

    Satoshi Muto, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Yuki Ozaki, Masayuki Watanabe, Takuya Inoue, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hiroyuki Suzuki

    Japanese Journal of Cancer and Chemotherapy ,  47 (9) 1287 - 1291 ,  2020.09

    Multiple Authorship ,  ISBN: 03850684

display all >>

Books 【 display / non-display

  • Immunotherapy of Cancer: An Innovative Treatment Comes of Age.

    Yamaguchi Yoshiyuki (Part:[Part 8]Immune-Related Response Criteria and Guidance for Clinical Trials. [Chapter 23]Immune-Related Response Criteria and Guidance for Clinical Trials.) (Page:337-346)

    Springer Japan ,  2016 ,  ISBN: 978-4-431-55030-3

    Suzuki Hiroyuki ,  Tokyo

Industrial Property 【 display / non-display

  • BIOMARKER FOR PROGNOSIS OF LUNG CANCER

    Industrial Property No PCT/JP2019/028945  2019.07.24  Unexpectedly No WO/2020/022361  2020.01.30 

    Patent

Presentations 【 display / non-display

  • Metabolites as mediator for alleviating adverse effects in chemotherapy: A new finding from a recent study of Japanese traditional Kampo medicine, rikkunshito (RKT).

    2019 ASCO Annual Meeting , 

    2019.05
    -
    2019.06

  • Surgical Clerkship Increasing Confidence to be a Surgeon

    The 119th Annual Congress of Japan Surgical Society , 

    2019.04
     
     

  • The Training System of Nurse Designated Procedures : A Promising Policy to Promote Doctor's Working Style Reform

    The 119th Annual Congress of Japan Surgical Society , 

    2019.04
     
     

  • Neutrophil-to-Lymphocyte Ratio Complements the Prognostic Ability of PD-L1 in Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors

    IASLC 19th World Conference on Lung Cancer , 

    2018.09
     
     

  • Uncommon EGFR Mutations as a Worse Prognostic Factor for Surgically Resected Lung Adenocarcinoma

    IASLC 19th World Conference on Lung Cancer , 

    2018.09
     
     

display all >>